Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9Y5W5
UPID:
WIF1_HUMAN
Alternative names:
-
Alternative UPACC:
Q9Y5W5; Q6UXI1; Q8WVG4
Background:
Wnt inhibitory factor 1 plays a crucial role in cellular processes by binding to WNT proteins, thereby inhibiting their activities. This protein is pivotal in the regulation of mesoderm segmentation, a key event in early embryonic development.
Therapeutic significance:
Understanding the role of Wnt inhibitory factor 1 could open doors to potential therapeutic strategies. Its involvement in the WNT signaling pathway suggests its potential in modulating processes critical for tissue development and regeneration.